A Phase 2 interventional study of BGJ398 in Solid Tumor and Hematologic Malignancies, sponsored by Novartis Pharmaceuticals. Terminated at 56 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Hematologic Neoplasms by Novartis — 1 open to participants now, 1 under way, 1 of them phase 3. Hematologic Neoplasms · Novartis.
Among the 18 studies in Hematologic Neoplasms by Novartis, this one is the 7th largest by enrollment, is one of 4 that started in 2014, is one of 9 in phase 2, and was the 13th registered.
1,445 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.
Browse Hematologic Neoplasms studies →1 of the 18 studies in Hematologic Neoplasms by Novartis is open now, in 5 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Belgium, Italy and 2 more countries
Ages 18+
By country, each count listing its studies:
Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger; 80 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 4
First in 2007; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 49 across the 18 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Hematologic Neoplasms by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this signal seeking study was to determine whether treatment with BGJ398 demonstrates sufficient efficacy in select FGFR pathway-regulated solid tumors and/or hematologic malignancies to warrant further study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient has a confirmed diagnosis of a select solid tumor (except with a primary diagnosis of Urothelial cell carcinoma, Cholangiocarcinoma, Endometrial cancer, and Glioblastoma multiforme) or hematologic and is in need of treatment because of progression or relapse.
Patient's tumor has been evaluated and pre-identified as having a tumor with a FGFR genetic alteration. The qualifying alteration must be assessed and reported by a CLIA-certified laboratory.
Patient must have received at least one prior treatment for recurrent, and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.
Patient must have progressive and per 1.1. or other appropriate hematological response criteria.
Patient has an (ECOG) performance status ≤ 1
Exclusion Criteria:
Patient has received prior treatment with BGJ398
Patients with Central Nervous System (CNS) or
Patient has received chemotherapy or other anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug.
Patients with acute or chronic pancreatitis
Patients with impaired cardiac function or cardiac diseases
History and/or current evidence of extensive tissue calcification
Use of medications that increase serum levels of phosphorus and/or calcium
Current evidence of corneal or retinal disorder/keratopathy
History and/or current evidence of renal or endocrine alterations of calcium/phosphate homeostasis
Patients with another primary within 3 years prior to starting study treatment, with the exception of adequately treated basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
Drug: BGJ398
BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
Clinical Benefit Rate (CBR) Associated With BGJ398 Treatment
Tumor Response: Overall response rate (ORR) and clinical benefit rate (CBR) for solid tumor (non-lymphoma) which excludes 3 TIO and 1 Lymphoma patients (hence 80 patients and not 84) Clinical benefit rate for patients with solid tumors were assessed using RECIST 1.1 and include responses of CR or PR or SD. For hematologic tumors other appropriate hematological response criteria may apply Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: 16 weeks
Overall Response (OR) or Partial Response (PR) or Greater
The key secondary endpoint, OR, was determined by Investigator assessment for each tumor assessment and defined as responses of CR and PR per RECIST version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months
Progression-Free Survival (PFS)
Kaplan-Meier estimates of PFS timing, months Progression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause
Time frame: every 8 weeks until death, assessed up to 24 months
Kaplan-Meier Estimates of PFS Rate, % (95% CI)
Time frame: Months 1, 2, 3, 4, 5, 6, 12, 18, 24
Overall Survival (OS)
Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause
Time frame: every 8 weeks until death, assessed up to 36 months
Kaplan-Meier Estimates of Survival Rate, % (95% CI)
Overall survival (OS) is the time from the date of start of treatment to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last contact.
Time frame: months 3, 6, 9, 12, 24
Number of Participants With 99 Day Minimum Duration of Response (DOR)
The duration of response (PR or greater) applies only to patients whose best response was PR or greater. It is defined as the Ttime from the first documented response to the date first documented disease progression or relapse or death due to any cause
Time frame: baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months
| Milestone | BGJ398 |
|---|---|
| Started | 84 |
| Completed | 0 |
| Not completed | 84 |
| Withdrew: Adverse event | 11 |
| Withdrew: Death | 2 |
| Withdrew: Disease progression | 57 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Non-compliance with study | 1 |
| Withdrew: Physician decision | 3 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Study terminated by by sponsor | 1 |
Tumor Response: Overall response rate (ORR) and clinical benefit rate (CBR) for solid tumor (non-lymphoma) which excludes 3 TIO and 1 Lymphoma patients (hence 80 patients and not 84) Clinical benefit rate for patients with solid tumors were assessed using RECIST 1.1 and include responses of CR or PR or SD. For hematologic tumors other appropriate hematological response criteria may apply Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
| Participants | BGJ398 |
|---|---|
| Complete response (CR) | 0 |
| Partial response (PR) | 6 |
| Progressive disease (PD) | 54 |
| Stable disease (SD) | 7 |
| Non-evaluable (NE) | 13 |
| Overall response rate (ORR: CR + PR) | 6 |
| Clinical benefit rate (CBR: CR+PR+SD) | 12 |
The key secondary endpoint, OR, was determined by Investigator assessment for each tumor assessment and defined as responses of CR and PR per RECIST version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
| participants | BGJ398 |
|---|---|
| Overall Response (OR) or Partial Response (PR) or Greater | 6 (2.8 to 15.6) |
Kaplan-Meier estimates of PFS timing, months Progression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause
| months | BGJ398 |
|---|---|
| Progression-Free Survival (PFS) | 1.8 (1.8 to 2.0) |
| percent of participants | BGJ398 |
|---|---|
| Month 1 | 88.0 (78.2 to 93.6) |
| Month 2 | 38.0 (27.0 to 48.9) |
| Month 3 | 32.3 (21.9 to 43.0) |
| Month 4 | 20.0 (11.5 to 30.1) |
| Month 5 | 15.4 (8.0 to 24.9) |
| Month 6 | 12.3 (5.8 to 21.3) |
| Month 12 | 10.2 (4.3 to 19.2) |
| Month 18 | 6.1 (1.8 to 14.5) |
| Month 24 | 0.0 (0.0 to 0.0) |
Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause
| months | BGJ398 |
|---|---|
| Overall Survival (OS) | 6.2 (4.4 to 9.8) |
Overall survival (OS) is the time from the date of start of treatment to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last contact.
| percent of participants | BGJ398 |
|---|---|
| Month 3 | 75.9 (64.9 to 83.9) |
| Month 6 | 50.1 (38.6 to 60.6) |
| Month 9 | 39.4 (28.5 to 50.1) |
| Month 12 | 35.1 (24.6 to 45.8) |
| Month 24 | 19.5 (10.5 to 30.5) |
The duration of response (PR or greater) applies only to patients whose best response was PR or greater. It is defined as the Ttime from the first documented response to the date first documented disease progression or relapse or death due to any cause
| Participants | BGJ398 |
|---|---|
| Number of Participants With 99 Day Minimum Duration of Response (DOR) | 6 |
Collected over Adverse Events (AEs) were collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit) up to maximum of 26.6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BGJ398 | 11/83 (13.3%) | 33/83 (39.8%) | 81/83 (97.6%) |
| Event | BGJ398 |
|---|---|
| SepsisInfections and infestations | 4/83 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/83 |
| AnaemiaBlood and lymphatic system disorders | 3/83 |
| NauseaGastrointestinal disorders | 3/83 |
| Urinary tract infectionInfections and infestations | 3/83 |
| Abdominal painGastrointestinal disorders | 2/83 |
| DiarrhoeaGastrointestinal disorders | 2/83 |
| DysphagiaGastrointestinal disorders | 2/83 |
| Large intestinal obstructionGastrointestinal disorders | 2/83 |
| VomitingGastrointestinal disorders | 2/83 |
| Event | BGJ398 |
|---|---|
| HyperphosphataemiaMetabolism and nutrition disorders | 47/83 |
| FatigueGeneral disorders | 44/83 |
| ConstipationGastrointestinal disorders | 26/83 |
| NauseaGastrointestinal disorders | 26/83 |
| Dry mouthGastrointestinal disorders | 22/83 |
| StomatitisGastrointestinal disorders | 22/83 |
| DiarrhoeaGastrointestinal disorders | 20/83 |
| Decreased appetiteMetabolism and nutrition disorders | 19/83 |
| Blood creatinine increasedInvestigations | 17/83 |
| DysgeusiaNervous system disorders | 17/83 |
Full Analysis Set (FAS): The FAS included all enrolled patients who received at least 1 dose of study drug. The FAS was the primary set for efficacy analyses.
| Age, Continuous(years) | BGJ398 |
|---|---|
| Mean | 60.2 ± 12.08 |
| Age, Customized(Participants) | BGJ398 |
|---|---|
| <65 years | 54 |
| >=65-<75 years | 21 |
| >=75 years | 9 |
| Sex: Female, Male(Participants) | BGJ398 |
|---|---|
| Female | 47 |
| Male | 37 |
| Race/Ethnicity, Customized(Participants) | BGJ398 |
|---|---|
| Caucasian | 74 |
| Black | 6 |
| Asian | 1 |
| Other | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jul 2014 to primary completion in Apr 2018, 45 months.
Results were first posted in Jun 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infigratinib